A number of other analysts have also weighed in on the stock. Stifel Nicolaus began coverage on shares of Crispr Therapeutics in a research note on Wednesday, March 4th. They issued a "hold" rating and a $52.00 price target for the company. ValuEngine raised shares of Crispr Therapeutics from a "sell" rating to a "hold" rating in a research note on Tuesday, March 3rd. Needham & Company LLC assumed coverage on shares of Crispr Therapeutics in a research note on Wednesday, April 29th. They set a "buy" rating and a $84.00 target price for the company. Citigroup increased their target price on shares of Crispr Therapeutics from $28.00 to $31.00 and gave the company a "sell" rating in a research note on Wednesday, March 4th. Finally, Piper Sandler reissued a "buy" rating and set a $104.00 target price on shares of Crispr Therapeutics in a research note on Wednesday, April 1st. One equities research analyst has rated the stock with a sell rating, five have given a hold rating and twelve have issued a buy rating to the stock. Crispr Therapeutics currently has an average rating of "Buy" and an average target price of $73.11.
Shares of NASDAQ:CRSP opened at $62.31 on Friday. The company has a 50 day moving average of $54.94 and a 200-day moving average of $55.71. The firm has a market cap of $3.89 billion, a P/E ratio of 83.08 and a beta of 2.26. Crispr Therapeutics has a twelve month low of $32.30 and a twelve month high of $74.00.
Crispr Therapeutics (NASDAQ:CRSP) last issued its quarterly earnings results on Tuesday, April 28th. The company reported ($1.15) earnings per share for the quarter, missing analysts' consensus estimates of ($1.05) by ($0.10). The company had revenue of $0.16 million during the quarter, compared to analyst estimates of $3.04 million. Crispr Therapeutics had a return on equity of 6.54% and a net margin of 15.73%. The company's revenue was down 52.1% on a year-over-year basis. During the same period in the prior year, the company posted ($0.93) earnings per share. Equities analysts forecast that Crispr Therapeutics will post -4.51 earnings per share for the current fiscal year.
In other Crispr Therapeutics news, President Rodger Novak sold 50,000 shares of the company's stock in a transaction that occurred on Tuesday, May 19th. The shares were sold at an average price of $65.00, for a total value of $3,250,000.00. Following the transaction, the president now owns 798,007 shares in the company, valued at approximately $51,870,455. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, COO Lawrence Otto Klein sold 25,000 shares of the company's stock in a transaction that occurred on Monday, May 11th. The shares were sold at an average price of $60.40, for a total transaction of $1,510,000.00. Following the completion of the transaction, the chief operating officer now owns 45,000 shares in the company, valued at approximately $2,718,000. The disclosure for this sale can be found here. In the last 90 days, insiders sold 85,693 shares of company stock valued at $5,458,039. 21.40% of the stock is owned by insiders.
Institutional investors have recently added to or reduced their stakes in the business. Franklin Resources Inc. increased its stake in Crispr Therapeutics by 2.6% in the 4th quarter. Franklin Resources Inc. now owns 435,644 shares of the company's stock valued at $26,533,000 after buying an additional 11,031 shares during the period. ARK Investment Management LLC increased its stake in shares of Crispr Therapeutics by 6.3% during the 4th quarter. ARK Investment Management LLC now owns 2,956,635 shares of the company's stock worth $180,074,000 after purchasing an additional 174,495 shares during the last quarter. Capital Advisors Inc. OK increased its stake in shares of Crispr Therapeutics by 9.4% during the 4th quarter. Capital Advisors Inc. OK now owns 127,029 shares of the company's stock worth $7,737,000 after purchasing an additional 10,872 shares during the last quarter. Advisory Services Network LLC increased its stake in shares of Crispr Therapeutics by 146.0% during the 4th quarter. Advisory Services Network LLC now owns 674 shares of the company's stock worth $41,000 after purchasing an additional 400 shares during the last quarter. Finally, Man Group plc acquired a new position in shares of Crispr Therapeutics during the 4th quarter worth $2,825,000. Hedge funds and other institutional investors own 57.96% of the company's stock.
About Crispr Therapeutics
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells.
Featured Article: Guidelines for Successful Channel Trading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected]
Every major global event brings with it changes to our national lexicon. Before the Covid-19 pandemic, few Americans knew what the initials PPE stood for. Today, virtually anyone knows that PPE stands for personal protective equipment.
At the onset of the mitigation policies, the goal of flattening the curve was being done to prevent our health care system from becoming overwhelmed. Part of that concern stemmed from a shortage of personal protective equipment. These are the masks, gloves, goggles and gowns that help protect medical workers against viral or bacterial infections.
As the novel coronavirus became labeled a global pandemic, the global mantra became to “flatten the curve” in an effort to prevent our healthcare system from being overwhelmed.
The United States is being referred to as being on a war time footing. Manufacturers that were already producing PPE have significantly ramped up capacity. And many companies are converting their excess manufacturing capacity to produce personal protective equipment.
In fairness, this may only be a reason for some of these companies to “keep the lights on” right now. But many of these companies have a good story to tell. And it’s that story that can make them solid investments in the future.